PBM-dAMDPhotobiomodulation Effects on Metabolic Changes in Dry AMD Patients

Study start date: July 11, 2022

INCLUSION CRITERIA * Male or female at least 50 years; * Subjects with ETDRS BCVA letter scores of between 50 and 80 (Snellen equivalent of 20/100 to 20/25); * Subjects with a diagnosis of dry AMD as defined by the presence of drusen (regular or reticular pseudodrusen) and/or geographic atrophy (GA) visible on two of the following: color fundus images, OCT and/or Heidelberg FAF; * Able to communicate well with the Investigator and able to understand and comply with the requirements of the study; The subject is informed of the nature of this study and has provided written informed consent in accordance with institutional, local, and national regulatory guidelines. EXCLUSION CRITERIA * Pregnant or lactating women * Current or history of neovascular maculopathy that includes any of the following: * Macular neovascularization (MNV) is defined as pathologic angiogenesis originating from the choroidal vasculature that extends through a defect in Bruch's membrane * Serous and/or hemorrhagic detachment of the neurosensory retina or retinal pigment epithelial (RPE) * Retinal hard exudates * Subretinal and sub-RPE fibrovascular proliferation * Disciform scar * Presence of center involving GA within the central ETDRS 500 μm diameter at diagnosis * Media opacities, including cataracts, which might interfere with visual acuity or imaging in the study eye(s). Subjects should not be entered if there is likelihood that they will require cataract surgery in the study eye in the next 24 months * Posterior capsule opacification, which might interfere with visual acuity or imaging in the study eye(s). Subjects should not be entered if there is likelihood that they will require surgery in the study eye in the next 24 months * Invasive eye surgery (e.g. cataract, capsulotomy) on a qualifying eye within three 3 months before treatment * Ocular disorder or disease that partially or completely obstructs the pupil (e.g., posterior synechia in uveitis) * A visually significant disease in any ocular structure apart from dry AMD (e.g., diabetic macular edema, glaucoma (using \>2 eye drops medications, uncontrolled IOP and/or central/paracentral visual field loss), glaucoma surgery, active uveitis, active vitreous disease, intraocular tumor, retinal vascular diseases) * Has a serious medical illness that will prevent the subject from performing study activities (including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease) or, in the judgment of the Investigator, is likely to require surgical intervention or hospitalization at any point during the study * Presence of or history of malignancy within the past 5 years other than non-melanoma skin or squamous cell cancer or cervical carcinoma in situ * Is non-ambulatory * Presence or history of known light sensitivity to yellow light, red light, or near-infrared radiation (NIR), or if there is a history of light-activated CNS disorders (e.g., epilepsy, migraine) * Use of any photosensitizing agent (e.g., topical, injectable) within 30 days of treatment without consulting the subject's physician * History of drug, alcohol, or substance abuse within 3 months before treatment * Has received an investigational drug or treatment with an investigational device within 3 months before treatment * If on any antioxidant or vitamin Age-Related Eye Disease Study (AREDS) supplement for dry AMD, has not been stabilized for a minimum of 1 month before Screening. Subjects are considered to be stable if they are taking the AREDS supplements consistently as prescribed by their treating doctor. * Has received Low Vision Rehab/Therapy within 30 days before Screening or intends to receive during the study * In the opinion of the Investigator, is unlikely to comply with the study protocol